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Abstract
Background and Objectives A clinical trial was conducted to measure and analyse the pharmacokinetic parameters of a lipid 
formulation of risperidone, VAL401. The VAL401 formulation is designed to repurpose risperidone from an antipsychotic to 
an adenocarcinoma treatment, with the lipid formulation altering the cellular uptake of risperidone, thus enabling anticancer 
biology to be exhibited in preclinical testing.
Methods This first human trial of VAL401 measured the concentrations of risperidone and its primary metabolite, 9-hydroxy-
risperidone, in the blood of patients after treatment with a single 2-mg dose of VAL401.
Results The trial provided information on differences in the pharmacokinetic profile of risperidone in VAL401 that may be 
caused by the formulation and/or the nature of the cancer patient population. VAL401 provided the following key pharma-
cokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised 
to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma 
concentration–time curve from time zero to infinity (AUC 0–∞), 58.2 ng h2/mL.
Conclusions Further comparisons of the pharmacokinetic parameters of risperidone and 9-hydroxyrisperidone in plasma of 
patients administered VAL401 and the corresponding parameters obtained from published data for conventionally formulated 
risperidone provide evidence for altered biological processing of VAL401 as compared to risperidone. The absolute values 
obtained provide support for future studies of VAL401 as a cancer treatment, as the Cmax demonstrates sufficient exposure 
to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports 
the use of the safety and tolerability data from conventional risperidone during future clinical trials.
Key Points 
Risperidone has been formulated into a lipid carrier 
system to be administered orally for use as a treatment 
for patients with lung cancer
Pharmacokinetic data demonstrate that exposure to risp-
eridone and its active metabolite, 9-hydroxy-risperidone, 
when using the lipid formulation is comparable to that 
reported in the literature for the conventional oral formu-
lation, with the exception of a reduced plasma half-life
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1 Introduction
Risperidone has a long history of use as an atypical antip-
sychotic; it appeared on the WHO list of essential medi-
cines in 2013 [1] and is the subject of positive Cochrane 
reviews supporting its use in schizophrenia [2]. Risperi-
done use is recognised to be beneficial against various 
behavioural and psychotic disorders in adults and adoles-
cents [3].
Off-label use in the palliative care of late-stage cancer 
patients has been reported, with positive benefits includ-
ing the treatment of opioid-induced nausea [4], allowing 
pain relief to be increased, and chemotherapy-induced 
delirium [5]. This use and the popularity of the drug con-
tinues despite the black box warning of the FDA against 
all antipsychotics of this group in relation to their use in 
elderly patients who potentially have dementia. This warn-
ing is due to an increased risk of death, reportedly due 
to cardiovascular events. Common side effects that are 
less serious are recognised to be weight gain, fatigue, and 
gynaecomastia in pre-pubescent males [6].
Several meta-analysis studies have proved contradictory 
and inconclusive as to whether typical and atypical antip-
sychotics have any additional direct anticancer or cancer-
protective benefits [7, 8].
Our preclinical studies showed that a formulation of 
risperidone with the naturally occurring conjugated lin-
oleic acid known as rumenic acid (9-cis,11-trans-linoleic 
acid) provides potential anticancer activity, while preclini-
cal testing of unformulated risperidone did not [9]. We 
postulated that the anticancer activity originates from the 
inhibition of the intracellular enzyme HSD10 (hydroxys-
teroid dehydrogenase type 10), and that the formulation 
facilitated this inhibition in vivo. Although HSD10 has 
not previously been the subject of oncology drug develop-
ment, reports of its mechanism of action are emerging in 
the literature [10, 11].
Herein, we start to explore how rumenic acid affects the 
pharmacokinetic distribution of risperidone in humans in 
order to establish whether it is reasonable to expect the 
VAL401 formulation, consisting of an equimolar ratio of 
risperidone to rumenic acid, to give different therapeutic 
outcomes as compared to simple risperidone when used 
in the cancer clinic. To facilitate the delivery of this mix-
ture, VAL401 has been formulated with lipid excipients—
a homogeneous liquid of Capryol PGMC, Lauroglycol 90, 
Capryol 90 and Aerosil 200.
We conducted a phase 2 clinical trial in late-stage non-
small cell lung cancer patients. The full trial objectives 
were to assess the safety, tolerability, pharmacokinet-
ics and efficacy of VAL401 in the treatment of patients 
with locally advanced or metastatic non-small cell lung 
adenocarcinoma, although only the pharmacokinetic 
parameters are provided in the present manuscript. By 
measuring the blood concentrations of both risperidone 
and its primary metabolite, 9-hydroxyrisperidone, after 
a single oral dose, the combined effect of the new for-
mulation in the specified population was compared with 
historic data on the absorption, metabolism and clearance 
of risperidone.
2  Methods
This open-label phase 2 clinical trial was conducted at two 
clinical sites in Tbilisi, Georgia, and identified by Clini-
calTrials.gov identifier NCT02875340 (EudraCT number: 
2016-000535-41). All procedures performed in the study 
were in accordance with the ethical standards of the insti-
tutional research committee. The principles of GCP were 
applied throughout and the study was completed according 
to the guidelines of the Declaration of Helsinki (1964) and 
later amendments to it. Local ethics approval was sought 
at each site for the initial protocol and for protocol amend-
ments. All participants provided written informed consent 
before commencing any study-related procedures.
2.1  Study Participants
Patients were recruited if they had a diagnosis of stage IIIB 
or IV non-small cell adenocarcinoma of the lung, whereby 
the disease was classified as measurable by RECIST 1.1 and 
was relapsed or metastatic after prior chemotherapy. The 
eligibility criteria required the patients to have an antici-
pated minimum 3-month life expectancy and to be capable 
of understanding, consenting to and complying with the 
protocol.
Exclusion criteria were radiotherapy or surgery within 
4 weeks prior to the first dose of VAL401 or chemother-
apy regimens with the potential for delayed toxicity within 
6 weeks prior. Patients displaying active or unstable brain 
metastases, active liver disease (including hepatitis B or C 
but excluding malignancy) or other active bacterial, viral 
or systemic fungal infections were also excluded from the 
study, as were patients who had displayed clinically signifi-
cant cardiac conditions within 3 months prior to the first 
dose of VAL401.
2.1.1  Study Treatment
VAL401 is a formulation of risperidone in a lipid excipient 
encapsulated in gelatin capsules for oral consumption. Each 
gelatin capsule contains 1 mg risperidone as the active phar-
maceutical ingredient along with an equimolar proportion 
of rumenic acid in a homogeneous liquid mixture consisting 
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of four excipients: Capryol PGMC (Gattefosse, France) and 
Lauroglycol 90 (Gattefosse France) as lipid-emulsifying 
agents, Capryol 90 (Gattefosse France) as a lipid-solubilis-
ing agent and Aerosil 200 (Gattefosse France) as a thicken-
ing and stabilising agent.
On day 1 of treatment, all patients were administered 
2 × 1 mg capsules of VAL401. This dosage was taken at 
least two hours after eating, and the capsules were swal-
lowed with water.
2.1.2  Pharmacokinetic Sampling
After the administration of 2 mg of VAL401 on day 1 of 
treatment, pharmacokinetic profiles were measured—with 
10 ml venous blood collected per sample (Vacuette tubes, 
EDTA anticoagulant)—at various time points: pre-dose and 
10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 10 h and 24 h 
after dosing.
After thorough mixing to ensure the blood samples were 
fully exposed to the EDTA anticoagulant in the collection 
tube, the samples were centrifuged at 2671×g for 4 min. 
After centrifugation, the plasma was separated and trans-
ferred into two screw-cap aliquot tubes with a minimum of 
2 ml of plasma per tube and then stored at − 2 to 8 °C, ready 
for analysis.
2.1.3  Bioanalytical Methods
Risperidone and 9-hydroxyrisperidone were measured 
according to the methods described by Fisher [12] and 
exemplified by Bowskill [13]. The plasma was extracted 
into butyl acetate:butanol (9 + 1, v/v) and a portion of the 
extract was analysed by LC-MS/MS (100 mm × 2.1 mm i.d. 
Waters Spherisorb S5SCX; eluent: 50 mmol/L methanolic 
ammonium acetate, pH 6.0; flow rate: 0.5 mL/min; positive 
ion APCI-SRM). The results were reported as ng/mL risp-
eridone and 9-hydroxyrisperidone. This analytical method 
provides concentrations between the lower level of quan-
tification of 2 ng/ml (below which the concentration was 
considered to be zero) and the upper limit for the assay of 
200 ng/ml (above which none of our samples fell). Analyses 
of internal quality control solutions containing both ana-
lytes at concentrations of 6 ng/ml, 15 ng/ml and 70 ng/ml 
were routinely interspersed with patient sample analyses. 
The accuracy and precision of this method are reported to 
be within 10% [12].
2.1.4  Pharmacokinetic Analysis
Pharmacokinetic parameters were determined from meas-
urements of the plasma concentrations of risperidone and 
9-hydroxyrisperidone at each sampling timepoint using non-
compartmental analysis as implemented with the R Core 
Team PK package [14, 15]. Briefly, in [15], the authors 
propose an approach based on Riemann sum and asymp-
totic estimators that does not require any assumption of a 
particular model.
Noncompartmental analysis via the PK package tends 
to overestimate the half-life due to the absorption time, 
which is not taken into account in the model [15]. The 
actual half-life is therefore shorter than the estimated 
reported half-life in this analysis, which can be consid-
ered a higher bound.
The “total active moiety”—the simple sum of the meas-
ured risperidone and 9-hydroxyrisperidone concentra-
tions—was calculated to allow a comparison with litera-
ture values for conventionally formulated risperidone. This 
approach was applied to mitigate the variability in slow and 
fast metabolisers of risperidone to 9-hydroxyrisperidone 
via the cytochrome P450 mechanism [16]. Hence, the total 
active moiety was calculated by summing the concentra-
tions of risperidone and 9-hydroxyrisperidone (the “com-
bined” approach) or by summing the values of the extracted 
parameters when appropriate (the “ParamSum” approach), 
as Riemann-sum-based calculations are sensitive to the 
number of sampling timepoints and values below the level 
of quantification, and several patients had measured con-
centrations below the level of quantification. By compar-
ing the distributions obtained through the “combined” and 
“ParamSum” approaches, we assessed whether our method 
could lead to the incoherent estimation of pharmacokinetic 
parameters.
2.1.5  Pharmacokinetic Parameters
Area under the plasma concentration–time curve from time 
zero to infinity (AUC 0–inf), clearance, mean residence time 
(MRT) and half-life were estimated. The following addi-
tional parameters were also extracted: volume of the distri-
bution at steady state (Vdss), clearance (Cl), area under the 
first moment curve  (AUMC0–inf) and area under the curve 
from the time of dosing to the last measurable concentration 
(AUC 0–t). The maximum peak concentration (Cmax) and time 
to maximum concentration (Tmax) were estimated using the 
maximum measured concentration value.
Considering that the dosage was administered orally, after 
the pharmacokinetic parameters had been calculated, they 
were adjusted to reflect an equivalent dose of 1 mg for each 
patient when determining Cmax, Clast, AUC and AUMC, as 
required by the method proposed in [15]. Given that the 
plasma concentration of risperidone can be considered to 
be proportional to the dose within the therapeutic range of 
1–16 mg daily dosage [17], Cmax, Clast, AUC and AUMC 
were dose-normalized to allow a straightforward compari-
son of our data with previously published data. The median 
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values of these previously published  pharmacokinetic 
parameters for risperidone, 9-hydroxyrisperidone, and the 
total active moiety are reported [18].
The AUC 0–inf distributions obtained using the “com-
bined” and “ParamSum” approaches were compared using 
Kolmogorov–Smirnov and Kruskal–Wallis tests. Given the 
nonsignificant p values obtained (Kolmogorov–Smirnov, 
p = 0.98; Kruskal–Wallis, p = 0.43), we concluded that the 
two distributions were similar: the limited number of sam-
pling timepoints did not lead to significant approximation 
errors when estimating the pharmacokinetic parameters.
3  Results
Eight eligible patients were recruited into the trial and 
therefore received at least one dose of VAL401 at 2 mg. At 
screening, these patients were observed to have a mean age 
of 65.8 years (range: 54–76 years) and a mean weight of 
68.3 kg (range: 56–82 kg). There were three female and five 
male participants. Four of the participants were recorded 
as being ex-smokers and four had never smoked. All eight 
participants identified themselves as non-Hispanic whites.
The concentration–time data collected for all eight patients 
on day 1 of dosing are displayed in graphical format in Fig. 
S1 and in tabular format in Table S1 of the electronic supple-
mentary material (ESM), with mean data presented in Fig. 1.
The product monograph for the traditional, immediate 
release, oral formulation of risperidone developed and mar-
keted by Janssen includes pharmacokinetic data, but only for 
a dosage of 1 mg. That study included 42 subjects with dif-
ferent ages and liver health profiles [19]. Since the pharma-
cokinetics of risperidone are considered proportional to the 
dose delivered within the therapeutic range of 1–16 mg daily 
dosage [17, 19], it is possible to convert the results obtained 
with the 2 mg dosage used in our study so that those results 
can be compared to the literature data for the conventional 
1 mg dosage. Demographic information on the subjects from 
the Janssen study of risperidone and the demographics of the 
patients administered VAL401 are summarised in Table 1.
Tables 2 and 3 show that risperidone and 9-hydroxyris-
peridone have different pharmacokinetic profiles regarding 
clearance and mean residence time or half-life when admin-
istered as the VAL401 formulation: their Cmax values are 
similar but the AUC is greater for 9-hydroxyrisperidone than 
for risperidone. The results from the “combined” and “Par-
amSum” approaches are shown in Table 2 and Table S2 of 
the ESM to allow comparison.
We also compared the pharmacokinetic parameter values 
obtained in our study with the data in the manufacturer’s 
monograph detailing the pharmacokinetics of risperidone (see 
Fig. 1  Mean concentrations in 
plasma plotted as time courses 
for risperidone (dotted line), its 
active metabolite 9-hydroxyris-
peridone (dashed line) and the 
total active moiety (the sum of 
the concentrations of risperi-
done and 9-hydroxyrisperidone, 
solid line). Each error bar 
represents the standard error of 
the mean (SEM)
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Tables 2 and 4). While the values calculated in the present 
work for the AUC, the Cmax and the clearance of risperidone 
alone and in combination with 9-hydroxyrisperidone are very 
similar to the manufacturer’s data, the half-life values from the 
present work are shorter, particularly that for the total active 
moiety. Since the clearance values are similar, this difference 
cannot be attributed to the elimination process. It may be due 
to differences in distribution, perhaps influenced by the lipid 
formulation, the patient’s disease state, or both.
4  Discussion
The use of lipids such as tri-, di- and monoglycerides and 
fatty acids in drug formulations dates back at least 50 years, 
with the principal aim being to improve oral availability 
[22]. More recently, researchers have introduced better-
characterised formulations, known as “nanostructured lipid 
carriers” (NLCs), with the same goal of increasing oral 
absorption [23], especially with poorly water-soluble class 
II drugs (which present high permeability but low solubil-
ity according to the Biopharmaceutics Classification Sys-
tem). For example, Mandpe et al. [18] reported a substantial 
increase in the oral bioavailability of iloperidone, which is 
chemically very similar to risperidone, in Wistar rats when 
the iloperidone was formulated in a NLC. However, risperi-
done is known to be well absorbed orally [24–26], so our 
motivation in this study was not to change the overall bio-
availability. Rather, research into iloperidone suggests that 
the presence of the lipid alters its absorption characteristics 
and thus, potentially, the pharmacokinetic distribution of 
iloperidone after intestinal absorption.
In this context, we note a recent series of papers on the 
pharmacokinetic fate, in mice, of the breast cancer treatment 
tamoxifen, another class II drug, when formulated in a NLC 
[27]. VAL401 is not a NLC, and tamoxifen is chemically 
different to risperidone. Nevertheless, that study of the phar-
macokinetic fate of a poorly soluble drug formulated with a 
lipid offers valuable insights. The researchers concluded that 
the presence of the lipid led to increased uptake of the drug 
via the intestinal lymphatic system, thus bypassing the “first 
pass” metabolism of the drug by cytochrome P450 enzymes 
in the liver. Consistent with their hypothesis, the half-life of 
tamoxifen in the mice was significantly longer than observed 
for a standard suspension of the drug.
Pharmacokinetic effects are predicted to be more com-
plex with lipid-formulated risperidone. The active moiety 
that provides the therapeutic benefit of risperidone is well 
known to be a combination of the drug itself and the metabo-
lite 9-hydroxyrisperidone, which arises from the action of 
cytochrome P450 enzymes, primarily in the liver [28]. Thus, 
in the case of risperidone, bypassing the liver could change 
the ratio of risperidone to 9-hydroxyrisperidone, potentially 
affecting the pharmacokinetics and therapeutic outcomes.
To explore this hypothesis further, we present Table 3, 
showing a comparison of 9-hydroxyrisperidone to risperi-
done pharmacokinetic parameter ratios. This again shows 
that when the overall populations of both studies are com-
pared, the half-life shows the greatest difference, but also 
that the data obtained in our study align most closely with 
the data obtained for the elderly subsection of patients 
reported by Janssen. These data suggest that the ratio of 
the AUC for 9-hydroxyrisperidone to the AUC for risperi-
done in our patients is the same as the corresponding ratio 
obtained when the risperidone was administered convention-
ally. Lymphatic uptake, if there was any, did not affect this 
ratio. On the other hand, the relatively slow appearance of 
both drug components in the blood in the present study as 
compared with Janssen’s study (Table 2) is consistent with 
Table 1  Summary of demographic information for the subjects in the Janssen study [18] and the patients in the VAL401 study
Parameter Subjects in the Janssen study [18] Lung-cancer 
patients adminis-
tered VAL401 in the 
present study
Young 
(count and 
mean ± SD)
Elderly 
(count and 
mean ± SD)
Liver disease 
(count and 
mean ± SD)
Moderate renal 
disease (count and 
mean ± SD)
Severe renal 
disease (count and 
mean ± SD)
All 
patients 
(count 
and 
mean)
No. of subjects 8 12 8 7 7 42 8
Gender
 Male 5 7 3 3 4 22 5
 Female 3 5 5 4 3 20 3
Age (years) 30 ± 4 69 ± 4 51 ± 12 56 ± 13 52 ± 13 52 65.8 ± 9
Age range 
(years)
25–35 65–78 35–73 34–68 29–66 38–64 54–76
Weight (kg) 78 ± 19 78 ± 16 85 ± 17 82 ± 18 78 ± 20 80 68.3 ± 9
Height (cm) 172 ± 15 169 ± 10 166 ± 11 170 ± 15 174 ± 9 170 169 ± 7
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a delayed appearance in the blood due to lymphatic uptake. 
Direct measurements of drug levels in the lymph would be 
needed to fully answer this question.
The requirement of this formulation for potential anti-
cancer activity goes some way to explaining the lack of 
clarity from previous meta-analyses, which did not control 
for dietary factors in order to accommodate the formu-
lation requirement. With rumenic acid being plentiful in 
dairy and beef products [29], it could be expected that the 
subjects included in the meta-analysis would only display 
a positive impact of risperidone against cancer if it was 
routinely taken with, for example, a glass of milk.
Table 2  Summary of the median values of pharmacokinetic param-
eters for risperidone, 9-hydroxyrisperidone and the combination 
of these two active molecules (as calculated using the “combined” 
approach) from the Janssen study [18] and the present study of 
patients administered VAL401
Subjects in the Janssen study [18] were administered 1  mg risperidone, whereas the patients in the present study were administered 2  mg 
VAL401. Dose-normalised (to 1 mg of risperidone) VAL401 pharmacokinetic parameter values are reported for Cmax, AUC 0–∞, AUC 0–last and 
 AUMC0–∞, as indicated by an asterisk
Data on the metabolite (9-hydroxyrisperidone) oral clearance  (Cloral) and volume of distribution at steady state (Vdss) were not available for the 
Janssen study subjects
– Data unavailable
Parameter Units Subjects in the Janssen study [18] Lung-cancer patients 
administered 
VAL401 in the pre-
sent study (median)
Young (median) Elderly 
(median)
Liver 
disease 
(median)
Moderate 
renal disease 
(median)
Severe renal 
disease 
(median)
All patients 
(mean + SD)
Risperidone
 Tmax h 1 1 1 1 1 1 ± 0 2
 Cmax ng/ml 5.33 6.37 8.16 9.6 9.65 7.8 ± 1.9 8*
 Clast ng/ml – – – – – – 1.5*
 t1/2 h 2.9 3.3 8.16 9.6 9.65 6.7 ± 3.4 3.5
 Vdss mL – – – – – – 113.9
 AUC 0–∞ ng·h/mL 23.5 26.2 35.9 65.8 48.6 40 ± 17.5 58.2*
 AUC 0–last ng·h/mL – – – – – – 49.8*
 AUMC0–∞ ng·h2/mL – – – – – – 237.9*
 Cloral mL/min 714 642 465 253 343 483.4 ± 194.6 286.4
 MRT h – – – – – – 5.1
9-Hydroxyrisperidone
 Tmax h 3 2 6.5 5 5 4.3 ± 1.8 8
 Cmax ng/ml 4.26 5,01 2.36 5.21 5.63 4.5 ± 1.3 5.8*
 Clast ng/ml – – – – – – 1.8*
 t1/2 h 16.5 23.4 17.9 27.2 33.6 23.7 ± 7 23.4
 Vdss mL – – – – – – 181
 AUC 0–∞ ng·h/mL 98.7 150 88.2 220 257 162.8 ± 74.1 276.3*
 AUC 0–last ng·h/mL – – – – – – 108.1*
 AUMC0–∞ ng·h2/mL – – – – – – 9295.8*
 Cloral mL/min – – – – – – 60.5
 MRT h – – – – – – 33.8
Total active moiety (risperidone + 9-hydroxyrisperidone) calculated using the “combined” approach
 Tmax h 2 1.5 1 1 2 1.5 ± 0.8 3
 Cmax ng/ml 9.1 10.2 8.5 13 13.3 13 ± 5.8 11.3*
 Clast ng/ml – – – – – – 7.3*
 t1/2 h 17 23 16 25 29 22 ± 5.5 9
 Vdss mL – – – – – – 73.3
 AUC 0–∞ ng·h/mL 132 189 145 272 417 231 ± 117.5 216.6*
 AUC 0–last ng·h/mL – – – – – – 88.3*
 AUMC0–∞ ng·h2/mL – – – – – – 4737.2*
 Cloral mL/min 127 89 119 61 40 87.2 ± 37.1 76.9
 MRT h – – – – – – 13
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Consideration of the off-label use in addition to the rec-
ognised side effects of risperidone provides support for 
its use in cancer patients, with the primary side effect of 
weight gain representing a benefit to patients suffering from 
cachexia [30], fatigue being a common and socially accept-
able side effect of oncology, and pre-pubescent males being 
readily excluded from the patient population.
However, the patient population of cancer sufferers is pre-
dominantly composed of elderly patients with a tendency 
to present dementia and potentially multiorgan dysfunction 
during end-stage disease, so it is important to first establish 
the safety and pharmacokinetic profile of the risperidone in 
the new lipid formulation. Variation in the pharmacokinetic 
profile from that of the conventionally formulated risperi-
done was expected when administering VAL401, due to the 
presentation of the pharmaceutical ingredient in a lipid (as 
detailed above) and the suboptimal medical condition of the 
patient population.
Snoeck et al. observed that the pharmacokinetics of ris-
peridone, 9-hydroxyrisperidone and the total active moiety 
varied with the population considered (young, elderly, liver 
disease or renal disease patients), with liver disease patients 
showing the lowest metabolism of risperidone to 9-hydroxy-
risperidone and age making very little difference. The age 
ranges considered in the present work support our intention 
to use the reported data on an elderly population for com-
parison, while noting that comorbidities will be many and 
varied in the late-stage cancer patients for whom VAL401 
is mainly intended [31].
Upon inspecting the data displayed in Table 2, it is clear 
that the AUC, Cmax and clearance values are comparable 
to those expected [20], but also that there is a decrease in 
the half-life of the total active moiety when using the lipid 
formation. With the caveats that our study population was 
small and highly comorbid, this singular difference in the 
Table 3  Metabolite-to-parent (i.e. 9-hydroxyrisperidone to risperidone) pharmacokinetic parameter ratios for each patient group in the Janssen 
study [18] and for the patients administered VAL401 in the present study
– Data unavailable
Parameter Subjects in the Janssen study [18] Lung-cancer patients 
administered VAL401 
in the present studyYoung Elderly Liver disease Moderate renal disease
Severe renal 
disease
All patients
9-Hydroxyrisperidone/risperidone pharmacokinetic parameter ratios
 Tmax 3.0 2.0 6.5 5.0 5.0 4.3 5.8
 Cmax 0.8 0.8 0.3 0.5 0.6 0.6 0.7
 Clast – – – – – – 1.2
 t1/2 5.7 7.1 2.2 2.8 3.5 3.5 6.7
 Vdss – – – – – – 1.6
 AUC 0–∞ 4.2 5.7 2.5 3.3 5.3 4.1 4.7
 AUC 0–last – – – – – – 2.2
 AUMC0–∞ – – – – – – 39.1
 Cloral – – – – – – 0.2
 MRT – – – – – – 6.6
Table 4  Summary of differences in median pharmacokinetic param-
eter values between VAL401 patients and elderly Janssen study sub-
jects  (JElderly), and between VAL401 patients and all Janssen study 
subjects  (JAll) for risperidone, 9-hydroxyrisperidone and the combi-
nation of them (i.e. the active moiety, as calculated using the “com-
bined” approach)
Where applicable, the differences in parameter values are dose-nor-
malised (to 1 mg dosage) for the VAL401 cohort, as indicated by an 
asterisk
– Data unavailable
Parameter Units VAL401 –  JElderly VAL401 –  JAll
Risperidone
 Tmax h 1 1
 Cmax ng/ml 2* 0.2*
 t1/2 h 0.2 − 3.2
 AUC 0–∞ ng·h/mL 32* 18*
 Cloral mL/min − 355.6 − 197
9-Hydroxyrisperidone
 Tmax h 3.7 3.7
 Cmax ng/ml 0.8* 1.3*
 t1/2 h 0 − 0,3
 AUC 0–∞ ng·h/mL 126* 113.5*
 Cloral mL/min – –
Total active moiety (risperidone + 9-hydroxyrisperidone) calculated 
using the “combined” approach
 Tmax h 1.5 1.5
 Cmax ng/ml 1* − 2*
 t1/2 h − 14 − 13
 AUC 0–∞ ng·h/mL 28* − 14*
 Cloral mL/min − 12.1 − 10.3
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observed pharmacokinetics supports the hypothesis that the 
active risperidone and 9-hydroxyrisperidone components 
remain associated with the lipid excipients of the formula-
tion after intestinal absorption.
The observed reduction in the half-life at approximately 
constant Cmax means that the volume of distribution Vdss is 
lower with VAL401 than with standard risperidone. Vdss is 
known to be affected by (among other factors) the degree to 
which the drug binds to proteins in the plasma. If more of 
the drug binds to plasma proteins, Vdss will be lower.
A further comparison of the parameter values in Table 2 
reveals that although the active moiety displays largely simi-
lar pharmacokinetic values to the conventionally formulated 
risperidone, Tmax for 9-hydroxyrisperidone was 8 h after 
VAL401 treatment but ranged from 2 h for elderly patients 
up to 6.5 h for liver-disease patients in the Janssen study. 
The later peak in the concentration of the main metabolite 
in our study supports the hypothesis of a delay in hepatic 
metabolism.
Interestingly, the plasma protein binding levels for ris-
peridone and 9-hydroxyrisperidone are rather different: 
approximately 89% and 74%, respectively [21]. Hence, a 
possible explanation for the difference in the pharmacoki-
netic profiles of VAL401 and conventionally formulated 
risperidone is that more of the active moiety is present 
as risperidone rather than 9-hydroxyrisperidone, leading 
to increased binding of the active moiety by plasma pro-
teins when using VAL401. This would be consistent with 
the likely increase in lymphatic uptake and decreased “first 
pass” hepatic metabolism.
As risperidone is a weakly basic drug, it would be 
expected to bind predominantly to α-1-acid glycoprotein 
(AAG) rather than albumin in the blood [32]. The AAG 
plasma concentration is seen as a prognostic tool for many 
cancers, including non-small cell lung cancer, with higher 
AAG concentrations correlating to poorer outcomes [33]. 
Hence, it may be expected that the plasma protein binding 
of risperidone would be greater in end-stage cancer patients 
than in noncancerous psychotic patients, which could 
explain the differences we observed. Note also that we are 
not aware of any research addressing the effect of lipids on 
plasma protein binding, which could be a further considera-
tion when attempting to explain these differences.
5  Conclusions
This study provided a first assessment of the pharmacoki-
netics of this new lipid formulation of risperidone after 
a single dose in this specialised end-stage cancer patient 
population. The exposure of the patients to the active moi-
ety was generally no greater with VAL401 than with the 
conventionally formulated risperidone, supporting the use 
of the safety and tolerability data for conventionally for-
mulated risperidone during further testing of VAL401 in 
the treatment of cancer.
Subsequent studies to explore the pharmacokinetics after 
multiple and differing doses of VAL401 would provide fur-
ther information, although it should be noted that both the 
parent risperidone and metabolite 9-hydroxyrisperidone 
should be analysed throughout. Further analyses were not 
possible during this study due to the ethical limitations of 
performing multiple blood draws from end-stage cancer 
patients.
The absolute Cmax value for the active moiety supports 
our supposition that 2 mg daily dosage would be sufficient 
to assess the potential anticancer activity of VAL401, as this 
would allow the desired level of 20 ng/mL (as tested in the 
previously reported in vitro model system [9]) to be attained.
Finally, although this study was developed with the inten-
tion to repurpose risperidone for use as a treatment for ade-
nocarcinoma, these pharmacokinetic data on a previously 
unexplored formulation may also be considered in the con-
text of the treatment of psychosis.
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